Novo Holdings’ $16.5B bid for Catalent; Novartis’ $2.9B bolt-on; Endpoints Slack interview with John Evans; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
In a week where the company behind a top obesity drug announced it will buy one of the biggest contract manufacturers of those drugs, other news could pale in comparison. But there’s plenty of other big stories on deals, earnings, senate hearings, people and more — see if you missed any.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.